Staar Surgical Co
STAAStaar Surgical Co (STAA) is a global provider of minimally invasive ophthalmic surgical products, specializing in designing, manufacturing, and marketing advanced implantable lenses and related instruments. The company focuses on solutions for refractive and cataract surgeries, aiming to improve visual outcomes for patients.
Company News
STAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The sto...
The global LASIK eye surgery market is projected to grow from USD 2.25 billion in 2025 to USD 3.77 billion by 2033, at a CAGR of 6.68%. Growth is driven by rising refractive disorders, AI-enabled surgical innovations, and expanding healthcare infrastructure. However, concerns over long-term safety complications such as corneal thinning and dry ey...
The global intraocular lens market is projected to grow from USD 5.97 billion in 2025 to USD 9.85 billion by 2033, driven by rising cataract prevalence, aging populations, and advanced lens technologies. However, high costs of premium lenses and limited accessibility in developing regions remain key challenges. North America leads the market with...
STAAR Surgical announced that shareholders did not approve its merger with Alcon Inc., which was valued at approximately $1.6 billion. The deal will be terminated with no termination fees owed by either party. STAAR will remain a standalone publicly traded company and focus on profitable growth and expanding its EVO ICL technology globally. Major...
Top investors of STAAR Surgical, including Yunqi Capital and Broadwood Partners, have rejected Alcon's revised acquisition offer of $30.75 per share, citing a flawed sale process and insufficient valuation.
